Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.5M Buy
11,664
+1,141
+11% +$134K 0.8% 37
2026
Q1
$1.27M Sell
10,523
-1,649
-14% -$190K 0.89% 37
2025
Q4
$1.28M Sell
12,172
-642
-5% -$60.3K 0.89% 35
2025
Q3
$1.08M Sell
12,814
-3,695
-22% -$304K 0.75% 38
2025
Q2
$1.31M Buy
16,509
+1,654
+11% +$131K 0.99% 27
2025
Q1
$1.33M Buy
14,855
+2,326
+19% +$217K 1.18% 26
2024
Q4
$1.25M Buy
12,529
+557
+5% +$57.4K 1.05% 27
2024
Q3
$1.36M Buy
11,972
+438
+4% +$52K 1.09% 29
2024
Q2
$1.43M Buy
11,534
+353
+3% +$45.5K 1.2% 25
2024
Q1
$1.48M Buy
11,181
+1,820
+19% +$224K 1.31% 21
2023
Q4
$1.02M Buy
+9,361
New +$972K 1.04% 33

Other funds holding MRK

Opinicus Capital's MRK Position: Q2 2026 in Review

Opinicus Capital increased its Merck (MRK) stake by 11% in Q2 2026, buying an estimated $134K and bringing the position to 11,664 shares worth $1.5M. The position accounts for 0.8% of the portfolio, ranked #37.

Opinicus Capital first reported a position in MRK in Q4 2023 and has held it in 11 quarters since. 1,752 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Opinicus Capital held 11,664 shares of Merck worth $1.5M as of Q2 2026.
  • Opinicus Capital bought 1,141 Merck shares in Q2 2026, an estimated $134K.
  • Merck made up 0.8% of Opinicus Capital's portfolio in Q2 2026, its #37 holding.
  • Opinicus Capital first reported a position in Merck in Q4 2023 and has held it in 11 quarters since.
  • 1,752 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Opinicus Capital's 13F filing for Q2 2026, filed 27 Jul 2026.